Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedEC
Euclidean Capital
Activity from announced rounds
Activity in this selectionSeries A
Euclidean Capital is the investor identified in Circle Pharma’s issuer announcement and by transaction counsel for InduPro.
Recorded funding activity
Circle Pharma develops macrocycle medicines using computational and structure-based methods. The recorded history also includes Savvy Wealth’s operating tools and investment support for financial advisors. Multiple Savvy entries remain separate events pending their own event-level review.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $30M 1 disclosed · full round size, not this investor’s share